Riskpilot← Back to searchSign inGet full accessScimoneg AB
ABIn liquidationOrg 5567377816Rental and operating of own or leased real estate · NACE 6820Est. 20073 employees
Revenue 2024
SEK 0
EBITDA margin
—
-204% vs 2023
Equity ratio
90.1%
Financial strength
Net profit 2024
SEK -67K
+63% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -70K | -204% |
| Net profit | SEK -67K | +63% |
| Total assets | SEK 404K | -20% |
| Equity | SEK 364K | -16% |
| Employees | 3 | — |
Legal name
Scimoneg AB
Org number
5567377816
Legal form
Aktiebolag
NACE code
6820 · Rental and operating of own or leased real estate
Founded
13 september 2007
Share capital
SEK 100 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Bolaget ska bedriva analys av biopolymerernas kemiska struktur, särskilt undersökning av nukleinsyrornas struktur som tjänst samt rådgivning på detta område, forskning och utveckling av metoder till strukturupplysning av högpolymera ämnen , beprövning, tillverkning och försäljning av biokemiska substanser (enzymer, substrat, nukleinsyror), utveckling, försäljning och uthyrning av apparater och dataprogram till analys av biopolymerer, förvärv och upplåtande av licenser i respektive område samt kooperation med andra företag för att utarbeta och marknadsföra gemensamma produkter, samt därmed förenlig verksamhet.
Address
Phone
+46708149143
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 559 | 7 019 | 8 408 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 438 | −1 020 | −2 887 | −23 | −70 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 438 | −1 020 | −2 887 | −23 | −70 |
| Net financials | −1 418 | 312 | −95 | −172 | 3 |
| Profit before tax | 61 | −8 | −2 982 | −195 | −67 |
| Tax | −3 | 81 | −0 | 15 | −0 |
| Net profit | 58 | 73 | −2 982 | −180 | −67 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 10 999 | 11 636 | 5 705 | 507 | 404 |
| Equity | 3 520 | 3 593 | 611 | 431 | 364 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 7 479 | 8 043 | 5 094 | 76 | 40 |
| Total debt | 7 479 | 8 043 | 5 094 | 76 | 40 |
EBITDA margin
-7000000.0%
This company
15.8%
Market median
-44303897% vs market
20202024
Equity ratio
90.1%
This company
38.2%
Market median
+136% vs market
20202024
Return on equity
-18.4%
This company
18.4%
Market median
-200% vs market
20202024
Net profit margin
-6700000.0%
This company
8.1%
Market median
-82716149% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
LB External Signatory | External Signatory | 2025 |
IM External Signatory | External Signatory | 2025 |
BJ External Signatory | External Signatory | 2025 |
UM External Signatory | External Signatory | 2025 |
EJ Liquidator | Liquidator | 2025 |
| Former (2) | ||
EK Chief Auditor | Chief Auditor | 2020 – 2025 |
JS Chief Executive Officer | Chief Executive Officer | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
| Chairman | 2024 – 2025 | |
| Chairman | 2020 – 2021 | |
| Board of Directors | 2021 – 2022 | |
| Chairman | 2021 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 | |
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EUROFINS GENOMICS EUROPE SEQUENTING GMBH
Scimoneg AB (this company)Board members of Scimoneg AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Birgitta Killgren Jonsson | External Signatory | 0 companies |
| Inger Margareta Dahle | External Signatory | 0 companies |
| Erik Karl Johan Grahnat | Chief Auditor | 0 companies |
| Jacob Sickmann Ransborg | Chief Executive Officer | 0 companies |
| Bengt Junior Niklas Nygårds | External Signatory | 0 companies |
| Ulrika Margareta Ahlholm | External Signatory | 0 companies |
| Emma Johanna Karin Carlstedt Haga | Liquidator | 0 companies |
| Ulrich August Werner Kuehle | Chairman | 0 companies |
| Tomi Thomas Kiratsopoulos | Chairman | 0 companies |
| Mats Olof Lindberg | Board of Directors | 0 companies |
| Michael Hadem | Chairman | 0 companies |